International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10371090" target="_blank" >RIV/00216208:11110/17:10371090 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1093/annonc/mdx097" target="_blank" >http://dx.doi.org/10.1093/annonc/mdx097</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/annonc/mdx097" target="_blank" >10.1093/annonc/mdx097</a>

Result language

angličtina

Original language name

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Original language description

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new &quot;basket&quot; clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [F-18]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of Oncology

ISSN

0923-7534

e-ISSN

—

Volume of the periodical

28

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

1436-1447

UT code for WoS article

000404134100010

EID of the result in the Scopus database

2-s2.0-85028014921